Abstract 4637: Olaparib in patients with pancreatic cancer with *BRCA1/2* inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Eugene R. Ahn[1], Elizabeth Garrett-Mayer[2], Susan Halabi[3], Pam K. Mangat[2], Carmen J. Calfa[4], Ajjai Alva[5], Vijay Suhag[6], Omid Hamid[7], Efrat Dotan[8], Eddy S. Yang[9], Olatunji Alese[10], Kathleen J. Yost[11], Alissa Marr[12], Martin Palmer[13], Forrest Thompson[14], Kaitlyn R. Antonelli[2], Andrew L. Rygiel[2], Sarah Anderson[2], Samiha Islam[2], Richard L. Schilsky[2]

[1]Cancer Treatment Centers of America, Chicago, IL; [2]American Society of Clinical Oncology, Alexandria, VA; [3]Duke University Medical Center, Durham, NC; [4]University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; [5]University of Michigan Rogel Cancer Center, Ann Arbor, MI, [6]Sutter Health Roseville Cancer Center, Roseville, CA; [7]The Angeles Clinic and Research Institute, Los Angeles, CA; [8]Fox Chase Cancer Center, Philadelphia, PA; [9]University of Alabama Birmingham Medical Center, Birmingham, AL; [10]Emory University Winship Cancer Institute, Atlanta GA; [11]Cancer Research Consortium of West Michigan, Grand Rapids, MI; [12]University of Nebraska Medical Center, Omaha, NE; [13]Swedish Cancer Institute, Edmonds, WA; [14]Levine Cancer Institute, Shelby, NC

Background:

- TAPUR is a phase II basket study that evaluates anti-tumor activity of commercially available targeted agents in patients (pts) with advanced cancers with specific genomic alterations.
- **Results of a cohort of pancreatic cancer (PC) pts with germline or somatic *BRCA1/2* inactivating mutations treated with olaparib (O) are reported.**

Methods:

Study Design:

- **Eligible pts:** Advanced PC, no standard treatment (tx) options, ECOG PS 0-2, adequate organ function, measurable disease. Tx assigned according to pre-specified matching rules based on genomic tests selected by sites.
- Pts received O tablets or capsules dosed at 300 mg (n=23) or 400 mg (n=7), respectively, orally BID until disease progression. Tumor evaluations performed at 8 and 16 wks then Q12 wks after treatment initiation.
- **Primary endpoint:** Disease control (DC) defined as objective response (OR) or stable disease (SD) at 16+ wks per RECIST v1.1. **Secondary endpoints:** progression-free survival (PFS), overall survival (OS), and toxicity per CTCAE. Grade 3-5 adverse events (AEs) or serious adverse events (SAEs) at least possibly related to O are reported.

Statistical Methods:

- Simon's optimal two-stage design used to test null hypothesis of 15% DC rate vs. alternative of 35%. Power = 85%; 1-sided α = 10%.
- ≥7 of 28 pts must achieve DC to reject null hypothesis and consider tx worthy of further study.

Olaparib has anti-tumor activity in heavily pre-treated patients with pancreatic cancer with germline or somatic *BRCA1/2* inactivating mutations.

Future Direction: Findings consistent with recent studies of O in this pt population. Further study warranted.

Results:

- 30 pts enrolled Nov 2016 to Aug 2019. 21 pts (70%) had *BRCA2* mutation; 9 (30%) had *BRCA1* mutation
- **Demographics**: Median age 60 y (range 44-79); 63% male; 26 pts White; 2 Asian; 2 Black
- **Clinical characteristics:** 30% PS 0, 57% PS 1, 13% PS 2; 53% received ≥3 prior systemic regimens; 47% received 1-2 prior regimens; 73% previously treated with platinum-based therapy
- **Outcomes**: 2 PR and 6 SD16+ (Table 1 and Figure 1). Time on O among pts with SD and OR is shown in Figure 2.
- **Safety:** 4 pts (13%) had ≥1 SAE or Grade 3 AE at least possibly related to O and consistent with previously reported AEs

Funding supported by AstraZeneca. The authors would like to acknowledge the patients who participated in this cohort as well as Josefa Briceno, MD, clinical lead of AstraZeneca, a TAPUR supporting pharmaceutical company.

Contact: TAPURPublications@asco.org

Table 1: Efficacy Outcomes (N=28)[1]	
DC rate, % (90% CI)	31 (18, 40)
OR rate, % (95% CI)	7 (0, 24)
1 year OS, % (95% CI)	48.2 (26.0, 67.3)

[1] *2 enrolled pts were not evaluable and are excluded from efficacy analyses*

Figure 1: OS and PFS in Pts with Advanced PC with *BRCA1/2* Inactivating Mutations Treated with O (N=28)



Figure 2: Time on Treatment in Pts with SD or OR (N=8)